In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
about
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsPlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.The evolving role of chemical synthesis in antibacterial drug discovery.Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugTedizolid phosphate.Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionProfile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsIn Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.Pipeline of Known Chemical Classes of Antibiotics.New antibiotic agents in the pipeline and how they can help overcome microbial resistance.In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Emerging drugs on methicillin-resistant Staphylococcus aureus.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Current and emerging drugs for acute bacterial skin and skin structure infections: an update.Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.The times they are a-changin': new antibacterials for skin and skin structure infections.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Tedizolid for treatment of acute bacterial skin and skin structure infections.Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report.New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsPharmacokinetics of Tedizolid in Obese and Nonobese Subjects.Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.
P2860
Q26853612-0F63405E-0ED0-411E-9326-4DB36C1CEB09Q33417790-1939B8E1-2297-4B0E-8021-9556A4FD0FF4Q33438834-805A65D9-9526-4D4A-9143-2D5A7A61CD0CQ34427652-9F6F680B-57FA-461A-851D-7C19F7F6D918Q34548251-32DEAC84-ECF7-499F-9CE7-03BF45827C22Q34612944-DFA0AECD-2383-4677-ABAB-0E8E26D898AEQ34922189-9949BF12-F6C7-4B85-BDC7-9F67303234FEQ35542330-D38F70BC-4763-4EB6-A1D9-40A9FE531388Q36075813-C00BC80B-1655-48F4-8AB5-09A710DCF578Q36683409-C0B6B121-F8D8-4040-B1F5-B7E610CC23A7Q36845895-2D95342A-7897-41AD-BB28-C9B609985363Q36969769-47873518-EB58-4433-926A-EEC7BC9C34CAQ38121142-0FDA36E4-6628-4A16-B344-52864359C761Q38171760-285693FA-ECF8-4521-845C-F948ECF7F19DQ38179460-47D06AD5-4292-483C-A558-24A000158F19Q38242081-6097F7BD-E91E-44BF-A896-C21009C7C409Q38352171-CC94263D-7775-4A2D-83B6-61489C911AF1Q38438503-A717E65E-0AA2-4B2A-AFD5-0895E6B04BD9Q38536296-2EEC19B0-3860-4678-9D5F-91C3420BFDB1Q38554583-8A13AF72-04C2-4D1C-A4A1-734566805CD0Q38641810-39F02AB4-8BCB-4606-8E99-D8A5F5905920Q38768071-199489F5-A470-4F4C-8E87-095D50430D5BQ38958278-535255D2-6585-4E3D-AB96-4B94240519D8Q39067666-97938B3D-C665-4508-BC17-8A4E295B358FQ40210571-DDD33225-CA02-4A0E-A286-A26F49E08555Q40633323-56104A67-5247-48BA-881A-BF1946EC7ECEQ41655310-41810C30-A22E-4802-A39D-37F5593ECD41Q41732849-B5521E35-7580-49DD-90FA-3017312A9FDDQ41996895-52036A3B-5A9B-45E4-BE30-1F632BA2C75DQ55511795-9A523C49-B522-4F37-A161-9465315F663D
P2860
In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vitro activity and microbio ...... and skin structure infections.
@ast
In vitro activity and microbio ...... and skin structure infections.
@en
type
label
In vitro activity and microbio ...... and skin structure infections.
@ast
In vitro activity and microbio ...... and skin structure infections.
@en
prefLabel
In vitro activity and microbio ...... and skin structure infections.
@ast
In vitro activity and microbio ...... and skin structure infections.
@en
P2093
P2860
P356
P1476
In vitro activity and microbio ...... and skin structure infections.
@en
P2093
Carisa Deanda
Chris M Pillar
Ken Bartizal
Philippe Prokocimer
P2860
P304
P356
10.1128/AAC.00458-12
P407
P577
2012-06-11T00:00:00Z